|
|
||||||||
Technical Briefs |
1 Department of Clinical Pathology and Division of Pulmonary and Critical Medicine,
2
Department of Medicine, Sungkyunkwan University School of Medicine and Samsung Medical Center, Seoul 135-710, Korea
aaddress correspondence to this author at: No. 50, Ilwon-dong, Kangnam-ku, Department of Clinical Pathology, Samsung Medical Center, Seoul 135-710, Korea; fax 82-2-3410-2719, e-mail jwonk@smc.samsung.co.kr
N-Acetyltransferase 2 (NAT2) metabolizes arylamines and hydrazines. The substrates of NAT2 include many therapeutic drugs, such as isoniazid (INH), as well as chemicals and carcinogens (1)(2)(3). For that reason, N-acetylation activity is associated with drug effects or toxicities and susceptibility to various cancers. The ability of NAT2 to N-acetylate arylamines is subject to a genetic polymorphism in the NAT2 gene. The acetylation rate and NAT2 genotype distribution are quite different among various populations. The genetic polymorphism in NAT2 has not been studied extensively in the Korean population. Previous reports were based only on phenotyping or restriction fragment length polymorphism analysis, leading to possible misclassification of genotypes. We therefore decided to investigate NAT2 allelic variability and genotype distributions in the Korean population by complete sequencing. We also evaluated the relationship between genotype and phenotype to understand N-acetylation pharmacogenetics.
One thousand Korean individuals who visited the health promotion center at Samsung Medical Center were anonymously studied. An additional 23 healthy volunteers and 18 patients with pulmonary tuberculosis participated in this study. DNA was extracted from peripheral blood leukocytes. We amplified a 1211-bp fragment that included an 870-bp protein-coding region of the NAT2 gene and performed full sequencing analysis (4) on an ABI Prism 377 DNA Sequencer (Perkin-Elmer). We then checked nucleotide substitutions by combined use of allele-specific-PCR (AS-PCR) and restriction enzyme digestion. Specific primers (5) for the wild-type and mutant alleles were used in separate PCRs to detect C282T, T341C, and G590A substitutions. The nucleotides at positions 190, 481, 590, 803, and 857 were explored by digesting the 1211-bp PCR fragment or AS-PCR product carrying the wild-type or mutant allele with NciI, KpnI, TaqI, DdeI, and BamHI, respectively. For phenotyping, the healthy volunteers and patients
Acknowledgments
References
The following articles in journals at HighWire Press have cited this article:
![]() |
C Kiyohara, M Washio, T Horiuchi, Y Tada, T Asami, S Ide, H Takahashi, G Kobashi, and The Kyushu Sapporo SLE (KYSS) Study Group Cigarette smoking, N-acetyltransferase 2 polymorphisms and systemic lupus erythematosus in a Japanese population Lupus, June 1, 2009; 18(7): 630 - 638. [Abstract] [PDF] |
||||
![]() |
R. J. Straka, R. T. Burkhardt, N. P. Lang, K. Z. Hadsall, and M. Y. Tsai Discordance Between N-acetyltransferase 2 Phenotype and Genotype in a Population of Hmong Subjects. J. Clin. Pharmacol., July 1, 2006; 46(7): 802 - 811. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Zhu, D. W. Hein, M. A. Doll, K. K. Reynolds, N. Abudu, R. Valdes Jr, and M. W. Linder Simultaneous Determination of 7 N-Acetyltransferase-2 Single-Nucleotide Variations by Allele-Specific Primer Extension Assay Clin. Chem., June 1, 2006; 52(6): 1033 - 1039. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |